Commemorating 100 years of immunotherapy
Mechanisms of allergen-specific immunotherapy

https://doi.org/10.1016/j.jaci.2010.11.030Get rights and content

Allergen-specific immunotherapy has been used for 100 years as a desensitizing therapy for allergic diseases and represents the potentially curative and specific method of treatment. The mechanisms of action of allergen-specific immunotherapy include the very early desensitization effects, modulation of T-and B-cell responses and related antibody isotypes, and migration of eosinophils, basophils, and mast cells to tissues, as well as release of their mediators. Regulatory T (Treg) cells have been identified as key regulators of immunologic processes in peripheral tolerance to allergens. Skewing of allergen-specific effector T cells to a regulatory phenotype appears as a key event in the development of healthy immune response to allergens and successful outcome in patients undergoing allergen-specific immunotherapy. Naturally occurring forkhead box protein 3–positive CD4+CD25+ Treg cells and inducible TR1 cells contribute to the control of allergen-specific immune responses in several major ways, which can be summarized as suppression of dendritic cells that support the generation of effector T cells; suppression of effector TH1, TH2, and TH17 cells; suppression of allergen-specific IgE and induction of IgG4; suppression of mast cells, basophils, and eosinophils; and suppression of effector T-cell migration to tissues. New strategies for immune intervention will likely include targeting of the molecular mechanisms of allergen tolerance and reciprocal regulation of effector and Treg cell subsets.

Section snippets

Very early mast cell and basophil suppression–related desensitization effect

Although decreases in IgE antibody levels and IgE-mediated skin sensitivity normally require years of SIT, most patients are protected against bee stings or tolerate skin late-phase response challenges at early stages of respective venom or grass pollen SIT.41, 42 An important observation starting from the first injection is an early decrease in mast cell and basophil activity for degranulation and systemic anaphylaxis (Fig 1). There is surprisingly little information about the mechanisms by

Conclusion

Allergen SIT and high-dose allergen exposure models represent efficient tools for the understanding of the mechanisms of action of curative treatment of allergic diseases and now enlighten the complex interactions of effector cells with tissues and Treg cells. In addition to allergy, these mechanisms might have implications in autoimmunity, organ transplant tolerance, tumor cell growth, parasite survival/clearance, and chronic infections. Suppression of an immune response by TR1 or FOXP3+ Treg

References (131)

  • G. Senti et al.

    Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy

    J Allergy Clin Immunol

    (2009)
  • V.M. Leb et al.

    Modulation of allergen-specific T-lymphocyte function by virus-like particles decorated with HLA class II molecules

    J Allergy Clin Immunol

    (2009)
  • J.N. Francis et al.

    Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy

    J Allergy Clin Immunol

    (2003)
  • E.M. Ling et al.

    Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease

    Lancet

    (2004)
  • A. Taylor et al.

    IL-10 inhibits CD28 and ICOS costimulations of T cells via src homology 2 domain-containing protein tyrosine phosphatase 1

    J Allergy Clin Immunol

    (2007)
  • A. Taylor et al.

    IL-10 suppresses CD2-mediated T cell activation via SHP-1

    Mol Immunol

    (2009)
  • S. Ito et al.

    Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine phosphorylation of STAT1

    Blood

    (1999)
  • A. Custovic et al.

    Current mite, cat, and dog allergen exposure, pet ownership, and sensitization to inhalant allergens in adults

    J Allergy Clin Immunol

    (2003)
  • T. Jartti et al.

    Association between CD4(+)CD25(high) T cells and atopy in children

    J Allergy Clin Immunol

    (2007)
  • L. Maggi et al.

    Demonstration of circulating allergen-specific CD4+CD25highFoxp3+ T-regulatory cells in both nonatopic and atopic individuals

    J Allergy Clin Immunol

    (2007)
  • K. Orihara et al.

    Circulating Foxp3+CD4+ cell numbers in atopic patients and healthy control subjects

    J Allergy Clin Immunol

    (2007)
  • G.J. Gleich et al.

    Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study

    J Allergy Clin Immunol

    (1982)
  • J. Bousquet et al.

    Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy

    J Allergy Clin Immunol

    (1988)
  • D.B. Golden et al.

    Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy

    J Allergy Clin Immunol

    (1982)
  • M. Jutel et al.

    Allergen-specific immunotherapy with recombinant grass pollen allergens

    J Allergy Clin Immunol

    (2005)
  • J. Reisinger et al.

    Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity

    J Allergy Clin Immunol

    (2005)
  • M. Akdis et al.

    Therapeutic manipulation of immune tolerance in allergic disease

    Nat Rev Drug Discov

    (2009)
  • M. Akdis et al.

    Mechanisms of allergen-specific immunotherapy

    J Allergy Clin Immunol

    (2007)
  • M. Larche et al.

    Immunological mechanisms of allergen-specific immunotherapy

    Nat Rev Immunol

    (2006)
  • S.R. Durham et al.

    Long-term clinical efficacy of grass-pollen immunotherapy

    N Engl J Med

    (1999)
  • G.B. Pajno et al.

    Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study

    Clin Exp Allergy

    (2001)
  • M. Wang et al.

    Peanut-induced intestinal allergy is mediated through a mast cell-IgE-FcepsilonRI-IL-13 pathway

    J Allergy Clin Immunol

    (2010)
  • M.C. Berin et al.

    T(H)2 adjuvants: implications for food allergy

    J Allergy Clin Immunol

    (2008)
  • T.A. Chatila et al.

    T-cell effector pathways in allergic diseases: transcriptional mechanisms and therapeutic targets

    J Allergy Clin Immunol

    (2008)
  • C.M. Kang et al.

    Interleukin-25 and interleukin-13 production by alveolar macrophages in response to particles

    Am J Respir Cell Mol Biol

    (2005)
  • Y.H. Wang et al.

    IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells

    J Exp Med

    (2007)
  • S.R. Dillon et al.

    Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice

    Nat Immunol

    (2004)
  • R. Kakkar et al.

    The IL-33/ST2 pathway: therapeutic target and novel biomarker

    Nat Rev Drug Discov

    (2008)
  • S. Finotto et al.

    Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet

    Science

    (2002)
  • T. Akkoc et al.

    Increased activation-induced cell death of high IFN-gamma-producing T(H)1 cells as a mechanism of T(H)2 predominance in atopic diseases

    J Allergy Clin Immunol

    (2008)
  • A. Trautmann et al.

    T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis

    J Clin Invest

    (2000)
  • N. Meyer et al.

    IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis

    J. Allergy Clin Immunol

    (2010)
  • K. Solarewicz-Madejek et al.

    T cells and eosinophils in bronchial smooth muscle cell death in asthma

    Clin Exp Allergy

    (2009)
  • S. Burgler et al.

    Differentiation and functional analysis of human T(H)17 cells

    J Allergy Clin Immunol

    (2009)
  • Y. Zheng et al.

    Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis

    Nature

    (2007)
  • H. Park et al.

    A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17

    Nat Immunol

    (2005)
  • P.R. Mangan et al.

    Transforming growth factor-beta induces development of the T(H)17 lineage

    Nature

    (2006)
  • L.E. Harrington et al.

    Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages

    Nat Immunol

    (2005)
  • S. Makihara et al.

    Regulation and characterization of IL-17A expression in patients with chronic rhinosinusitis and its relationship with eosinophilic inflammation

    J Allergy Clin Immunol

    (2010)
  • P. Martin et al.

    The leukocyte activation antigen CD69 limits allergic asthma and skin contact hypersensitivity

    J Allergy Clin Immunol

    (2010)
  • Cited by (0)

    Series editors: Joshua A. Boyce, MD, Fred Finkelman, MD, William T. Shearer, MD, PhD, and Donata Vercelli, MD

    Supported by the Swiss National Foundation grants 320030_125249/1 and 320030_132899 and the Christine Kühne Center for Allergy Research and Education (CK-CARE).

    Terms in boldface and italics are defined in the glossary on page 19.

    View full text